Nkarta (NKTX) risk factors, FY2025 10-K

Risks Related to our Financial Position

1. 01We have a limited operating history and do not have any products approved for sale
2. 02We have incurred significant losses since our inception, and we expect to continue to incur significant losses for the foreseeable future
3. 03We have never generated revenue from product sales and may never achieve or maintain profitability
4. 04attracting, hiring and retaining qualified personnel
5. 05We will require additional capital, which, if available, may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates
6. 06Impairment of our long-lived assets could have a material adverse effect on our financial condition and results of operationsNew

Risks Related to Our Business and Industry

1. 07Our business depends upon the success of our CAR NK-cell technology platform
2. 08Utilizing CAR NK cells represents a novel therapeutic approach, and we must overcome significant challenges in order to develop, commercialize and manufacture our product candidates
3. 09Clinical development involves a lengthy and expensive process with an uncertain outcome, and we may encounter substantial delays due to a variety of reasons outside our control
4. 10failure of ourselves or any third-party manufacturers, contractors or suppliers to comply with regulatory requirements, maintain adequate quality controls, or be able to provide sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates
5. 11Our business is highly dependent on the clinical success of our product candidates, and on the clinical success of NKX019, in particular, and we may fail to develop NKX019 and/or our other product candidates successfully or be unable to obtain regulatory approval for them71% rewritten
6. 12Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be delayed, made more difficult or rendered impossible by multiple factors outside our control
7. 13our ability to manufacture the requisite supply of our product candidates for our clinical trials; and25% rewritten
8. 14Certain aspects of the function and production of CAR NK cells are currently unknown or poorly understood, and may only become known through further preclinical testing and clinical trials. Any potential re-engineering required may result in delays and additional expenses83% rewritten
9. 15If any of our product candidates, or any competing product candidates, demonstrate relevant, serious adverse events, we may be required to halt or delay further clinical development
10. 16If we fail to compete effectively with academic institutions and other biopharmaceutical companies that develop similar or alternatives to cellular immunotherapy product candidates, our business will be materially adversely affected
11. 17Our preclinical pipeline programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all
12. 18the FDA not allowing us to rely on previous findings of safety and efficacy for other similar but approved products and published scientific literature
13. 19collaboration agreements may restrict our right to independently pursue new product candidates
14. 20We may seek special designations by the regulatory authorities to expedite regulatory approvals, but may not be successful in receiving such designations, and even if received, they may not benefit the development and regulatory approval process
15. 21We may seek and obtain orphan drug designation for our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity
16. 22Public opinion and scrutiny of cell-based immunotherapies may impact public perception of our company and product candidates, or impair our ability to conduct our business
17. 23We may not identify or discover other product candidates and may fail to capitalize on programs or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success
18. 24a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors
19. 25If third parties that we rely on to conduct clinical trials do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our product candidates
20. 26form relationships with other entities, some of which may be our competitors
21. 27interruption or delays to our discovery and clinical activities
22. 28If we are not able to establish pharmaceutical or biotechnology collaborations on commercially reasonable terms, or at all, we may have to alter our development and commercialization plans
23. 29We may need to increase the size of our organization, and we may experience difficulties in managing growth
24. 30If we fail to attract and retain senior management, clinical, and key scientific personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize our product candidates
25. 31Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop
26. 32The increasing use of social media platforms presents new risks and challenges
27. 33Our insurance policies may be inadequate, may not cover all of our potential liabilities and may potentially expose us to unrecoverable risks
28. 34Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business
29. 35Our business could be negatively impacted by the failure to address evolving environmental, social, and corporate governance matters79% rewritten

Risks Related to Manufacturing

1. 36Our manufacturing process is novel and complex, and we may encounter difficulties in production, or difficulties with internal manufacturing, which would delay or prevent our ability to provide a sufficient supply of our product candidates for clinical trials or our products for patients, if approved65% rewritten
2. 37that we will not have sufficient quantities of such materials or product candidates, or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization effortsNew
3. 38the possible termination or nonrenewal of the agreement by the third-party at a time that is costly or inconvenient for us
4. 39We are reliant on a sole supplier for certain steps of our manufacturing process27% rewritten
5. 40Delays in commissioning and receiving regulatory approvals for our manufacturing facilities could delay our development plans and thereby limit our ability to develop our product candidates and generate revenues
6. 41shortages of qualified personnel, raw materials or key contractors
7. 42The optimal donor and manufacturing parameters for our product candidates have not been definitively established, which may hinder our ability to optimize our product candidates or to address any safety or efficacy issues that may arise
8. 43We are dependent on third parties to store our CAR NK cells, viral vector, master and working cell banks of NKSTIM cells, and any damage or loss would cause delays in replacement, and our business could suffer
9. 44We have not yet developed a validated methodology for freezing and thawing commercial-scale quantities of CAR NK cells, which we believe will be required for the storage and distribution of our CAR NK-cell product candidates

Risks Related to Our Intellectual Property

1. 45If any patent protection we obtain is not sufficiently robust, our competitors could develop and commercialize products and technology similar or identical to ours
2. 46Claims brought against us for infringing, misappropriating or otherwise violating intellectual property rights of third parties or engaging in unfair competition, would be costly and time-consuming and could prevent or delay us from successfully developing or commercializing our product candidates
3. 47We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which could materially adversely affect our ability to develop, manufacture and market our product candidates
4. 48Our development and commercialization rights to our current and future product candidates and technology are subject, in part, to the terms and conditions of licenses granted to us by others
5. 49Duration of patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time, and the expiration of our patents may subject us to increased competition
6. 50Even after issuance, our owned and in-licensed patents may be subject to challenge, which if successful could result in a partial or complete loss of patent rights, which could materially adversely affect our ability to protect our competitive position
7. 51Even if our patents are determined to be valid and enforceable, they may not be interpreted sufficiently broadly to prevent others from marketing products similar to ours or designing around our patents
8. 52We may not be able to effectively monitor unauthorized use of our intellectual property and enforce our intellectual property rights against infringement, and may incur substantial costs as a result of bringing litigation or other proceedings relating to our intellectual property rights
9. 53We may also, from time to time, seek to enforce our intellectual property rights against infringers when we determine that a successful outcome is probable and may lead to an increase in the value of the intellectual property
10. 54We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection
11. 55Changes in U.S. patent law or the patent law of other jurisdictions could decrease the certainty of our ability to obtain patents and diminish the value of patents in general, thereby impairing our ability to protect our current and any future product candidates
12. 56We may fail to obtain or enforce assignments of intellectual property rights from our employees, consultants and contractors
13. 57If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and product candidates could be materially diminished
14. 58The U.S. government could choose to exercise certain rights in technology developed under government-funded research, which could eliminate our exclusive use of such technology or require us to commercialize our product candidates in a way we consider sub-optimal

Risks Related to Commercialization

1. 59If any of our product candidates are approved for marketing and commercialization and we have not developed or secured marketing, sales and distribution capabilities, either internally or from third parties, we will be unable to successfully commercialize such products and may not be able to generate product revenue
2. 60Our product candidates, including NKX019, could be subject to regulatory limitations following approval, if and when such approval is granted
3. 61imposition of civil or criminal penalties
4. 62The market opportunities for our product candidates, if and when approved, may be limited, and if such market opportunities are smaller than we expect, our revenues could be materially adversely affected and our business could suffer
5. 63The commercial success of any of our product candidates will depend upon such product candidate’s degree of market acceptance by physicians, patients, third-party payors and others in the medical community
6. 64Even if a product candidate displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after such product is launched. Our product candidates may not achieve broad market acceptance
7. 65The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market such products and to generate product revenue
8. 66Healthcare reform initiatives and other administrative and legislative proposals may harm our business
9. 67establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending
10. 68Obtaining and maintaining marketing approval or commercialization of our product candidates in one jurisdiction does not mean that we will be successful in obtaining marketing approval of our product candidates in other jurisdictions
11. 69business interruptions resulting from geopolitical actions, including war and terrorism, natural disasters including earthquakes, typhoons, floods and fires, and other public health crises, illnesses, epidemics or pandemics
12. 70Our business operations and relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable fraud and abuse and other healthcare laws and regulations, which could expose us to penalties
13. 71We may fail to comply with evolving global privacy laws30% rewritten

Risks Related to Our Common Stock

1. 72The trading price of our common stock is likely to be highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control
2. 73other factors discussed in these risk factors
3. 74Concentration of ownership of our shares of common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions
4. 75A significant portion of our total outstanding shares are eligible to be sold into the market, which could cause the market price of our common stock to drop significantly
5. 76We are a “smaller reporting company” and we rely on exemptions from certain disclosure and governance requirements applicable to smaller reporting companies, as a result of which our common stock may be less attractive to investors83% rewritten
6. 77Our severance and change in control agreements with our executive officers may require us to pay severance benefits to any of those persons who are terminated, which could materially adversely affect our financial condition or results of operations
7. 78Our ability to use our net operating loss carryovers and certain other tax attributes may be limited
8. 79We do not expect to pay any cash dividends to the holders of our common stock for the foreseeable future
9. 80Provisions in our certificate of incorporation, our bylaws and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management
10. 81In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us
11. 82Our certificate of incorporation includes a forum selection clause, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us
12. 83other action asserting a claim against us that is governed by the internal affairs doctrine
13. 84Computer system interruptions or security breaches of our information systems could significantly disrupt our product development programs and our ability to operate our business
14. 85The misuse of artificial intelligence could adversely impact our business, including by posing security risks to our confidential information, proprietary information and personal dataNew
15. 86Our business is affected by macroeconomic conditions, including rising inflation, interest rates and supply chain constraints57% rewritten
16. 87Any acquisitions or strategic collaborations may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities or subject us to other risks
17. 88our inability to generate revenue from acquired drugs, intellectual property rights, technologies, and/or businesses sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs
18. 89We could be subject to securities class action litigation
19. 90If securities analysts do not publish research or reports about our business or if they publish negative reports or downgrade our stock, the price of our common stock could decline
20. 91We incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives
21. 92Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
22. 93Changes to, or interpretations of, financial accounting standards may affect our results of operations and could cause us to change our business practices